Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smell lost to COVID? nasal steroid rinse shows promise in trial

NCT ID NCT04361474

Symptom relief Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a budesonide nasal rinse (a steroid) could improve smell loss in 120 adults who still had trouble smelling 30 days after a mild COVID-19 infection. Participants used the rinse twice daily for 30 days, along with smell training. The goal was to see if more people gained at least 2 points on a smell test compared to those using only a saltwater rinse.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
budesonide (a corticosteroid) given as a nasal rinse
What this could lead to
If it works, this could offer a simple, at-home treatment to help people regain their sense of smell after COVID-19.
What could go wrong
This is a small, completed trial, and the results may not apply to everyone. The treatment is not yet approved for this use, and corticosteroids carry some risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

120 people

The number who actually took part.

Started

May 2020

Finished

Jun 2021

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient over 18 years of age; * Patient with a suspected SARS-CoV-2 infection in a epidemic context, whether or not confirmed by PCR, or contact close to a PCR-confirmed case, typical chest CT scan (unsystematized frosted glass areas predominantly sub-pleural, and at a later stage of alveolar condensation with no excavations neither nodules nor masses) or positive serology ; * Patient with isolated acute hyposmia persisting at D30. of the onset of signs of CA-MRSA-CoV-2 infection; * Absence of PCR-confirmed SARS-CoV-2 portage at the time of inclusion Exclusion Criteria: * Known hypersensitivity to budesonide or to any of the excipients of the medicine; * Hemostasis disorder, or epistaxis; * Oromo-oral-nasal and ophthalmic herpes virus infection; * Long-term corticosteroid treatment; * Treatment with potent CYP3A4 inhibitors (e.g., CYP3A4 inhibitors); ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and HIV proteases) ; * Forms of CoV-2-SARS with respiratory signs or other than anosmia persisting at 30 days from the onset of symptoms; * Hyposmia persisting for more than 90 days after onset of symptoms; * Other causes of hyposmia revealed on interrogation or an MRI;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anosmia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anosmia COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anosmia Budesonide Olfaction disorders SARS-CoV-2

Contacts and locations

Locations

  • Amélie YAvchitz

    Paris, 75019, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.